



## OMICs and Complex Diseases

### Collection Editors:

#### **Dr. Mostafa Dianatinasab**

Department of Complex Genetics  
and Epidemiology, School of  
Nutrition and Translational  
Research in Metabolism,  
Maastricht University, 6228 GR  
Maastricht, The Netherlands

#### **Dr. Anke Wesselius**

Department of Epidemiology,  
CAPHRI Care and Public Health  
Research Institute, Maastricht  
University, 6229ER Maastricht,  
The Netherlands

#### **Dr. Amin Salehi-Abargouei**

Nutrition and Food Security  
Research Center, Shahid  
Sadoughi University of Medical  
Sciences, Yazd, Iran

### Message from the Collection Editors

Omics, which includes genomes, epigenomics, lipidomics, transcriptomics, proteomics, microbiomics, and metabolomics, is a fast-developing, multi-disciplinary, and growing discipline. In ways that were previously unimaginable, each of these domains provides the opportunity to comprehend and observe science from a global perspective. High-throughput methodologies can rapidly provide a global picture of the processes within cells at multiple levels, allowing for accelerated discoveries in health and disease.

Although the results of "omics" are still preliminary and little is known from large epidemiological studies, it is believed that they are inevitably important technologies for future discoveries in health and disease.

Recent breakthroughs in "omics" technologies have opened up various new opportunities for novel discoveries in the diagnosis, treatment, and prevention of diseases. These new "omics" technologies have the potential to significantly improve our understanding of the complex relationships that exist between lifestyle (food and nutrients), metabolism, and complex diseases.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)